Biochemical and molecular genetic studies have recently suggested that mutations in the gene coding for fibrillin on chromosome 15 result in Marfan syndrome. To our knowledge, only one mutation in the fibrillin gene has been published. Here we report the results of screening 20 unrelated MES patients for mutations in fibrillin cDNA by the singlestrand conformation polymorphism technique. We found two mutations, both of which appear in the heterozygote form and code for a shortened fibrillin polypeptide. The first mutation is a large in-frame deletion of 366 bases of the fibrillin mRNA, shown to result in a truncated but secreted polypeptide found in the fibroblast culture of the patient. The second mutation is a G-to-A transition resulting in the substitution of a stop codon for a tryptophan codon and thus predicting the premature termination of the polypeptide chain. We screened 60 other, unrelated MFS patients for these mutations as well as for the previously reported mutation (arginine-239 to proline) and found none of the three mutations in any of these patients. These data suggest that most MFS families carry their own distinct mutation.
ABSTRACT
Biochemical and molecular genetic studies have recently suggested that mutations in the gene coding for fibrillin on chromosome 15 result in Marfan syndrome. To our knowledge, only one mutation in the fibrillin gene has been published. Here we report the results of screening 20 unrelated MES patients for mutations in fibrillin cDNA by the singlestrand conformation polymorphism technique. We found two mutations, both of which appear in the heterozygote form and code for a shortened fibrillin polypeptide. The first mutation is a large in-frame deletion of 366 bases of the fibrillin mRNA, shown to result in a truncated but secreted polypeptide found in the fibroblast culture of the patient. The second mutation is a G-to-A transition resulting in the substitution of a stop codon for a tryptophan codon and thus predicting the premature termination of the polypeptide chain. We screened 60 other, unrelated MFS patients for these mutations as well as for the previously reported mutation (arginine-239 to proline) and found none of the three mutations in any of these patients. These data suggest that most MFS families carry their own distinct mutation.
The Marfan syndrome (MFS) is an autosomal dominant connective-tissue disorder characterized by cardiovascular, ocular, and skeletal manifestations (1) . By the random linkage approach, the MFS locus was assigned to the long arm of chromosome 15 in three Finnish families (2) . Later, the linkage was confirmed in families from diverse ethnic backgrounds, and the locus was more precisely localized to the immediate vicinity of the polymorphic marker DISSI (3) (4) (5) . To date, linkage analyses of chromosome 15 markers in families from different populations have not revealed any evidence for genetic heterogeneity underlying MFS (3) (4) (5) .
Independent simultaneous immunohistochemical analyses demonstrated a nearly constant deficiency of fibrillin, an extracellular protein (6) , in skin sections and cultured fibroblasts from MFS patients (7) . Subsequently, the fibrillin cDNA was cloned (8) and the corresponding locus was mapped by in situ hybridization to chromosome 15q21.1 (9, 10) , in the vicinity of the marker DJSSI. The (17) .
Single-Strand Conformation Polymorphism (SSCP) Analyses and Characterization of the Mutations. For SSCP analyses (18, 19) , first-strand cDNA was synthesized from 1,g oftotal RNA by 20 units of avian myeloblastosis virus reverse transcriptase (Promega) using the fibrillin-specific primers 3b, 6b, and 9b ( Fig. 1) . One-tenth of the cDNA synthesized with primer 3b was then used as a template to amplify overlapping fragments ofthe fibrillin cDNA by PCR (20) with each of the following primer pairs: la/b, 2a/b, and 3a/b. Analogously, cDNA synthesized with primer 6b was used as a template for amplification using the primer pairs 4a/b, 5a/b, and 6a/b, and cDNA synthesized with the primer 9b was used as a template for amplification using the primer pairs 7a/b, 8a/b, and 9a/b (Fig. 1) . The PCR products were radiolabeled by adding 1 ,Ci (37 kBq) of [a-32P]dCTP (Amersham) to the PCR mixture. The PCR was carried out for 30 cycles in a programmable heating block (Techne PHC-1) with denaturation at 95°C for 1 min, annealing at 60°C for 1 min (except for the primer pair lla/b, 58°C for 1 min), and extension at 72°C for 1-10 min. The conditions for PCR were as previously described (21) . Before the SSCP analyses the PCR products larger than 500 bp were cleaved to two fragments by restriction enzyme digestion. Four microliters of the PCR mixture was digested with 30 units of restriction enzyme in a total volume of 60,l. Two microliters of0.3% SDS/30 mM EDTA was added to 4 ,ul of the digestion reaction, and 6 ,ul of 95% (vol/vol) formamide/20 mM EDTA, 0.05% bromphenol blue/0.05% xylene cyanol was added. The sample was denatured at 80°C for 2 min and applied (3 ,ul per lane) to a nondenaturing 5% polyacrylamide gel. Electrophoresis was carried out at two conditions: one gel contained 10% (vol/ vol) glycerol in 90 mM Tris borate, pH 8.3/4 mM EDTA (1 x TBE buffer) and the other gel contained 5% glycerol in 0.5 x TBE buffer. In both cases the gels were run at 15 W for 15 hr at room temperature. The gels were dried and the bands were visualized by autoradiography for 5-24 hr with Kodak X-Omat AR film and an intensifying screen.
Sequence Analyses of PCR Products. The amplified DNA fragments were purified by electrophoresis through a 1% agarose gel. The band was excised, crushed into 10 mM Tris, pH 8.0/1 mM EDTA, extracted with phenol, quickly frozen in liquid N2, and centrifuged. After extraction with chloroform the DNA was precipitated with ethanol and sequenced by the dideoxynucleotide termination method (22) with modifications (23) . Sequencing of the individual fragments was carried out with corresponding PCR primers as sequencing primers.
Solid-Phase Minisequencing. Genomic DNA was screened for the G-to-A point mutation at nt 5574 and the R239P mutation by the solid-phase minisequencing method (24) with the conditions previously described (21) . The DNA was amplified by using either primer 10a and 5'-biotinylated primer 10b or primers lla (5'-biotinylated) and llb. The amplified 5'-biotinylated DNA was then immobilized in a streptavidin-coated microtiter well and denatured at high pH. The mutation was detected by a one-step primer extension reaction directed by primer ( DNA directly upstream of the mutation. In this reaction, one labeled dNTP corresponding to the nucleotide at the site of the mutation was incorporated by a DNA polymerase. This method is simple and reliable and the results of the test are obtained as numeric values that unequivocally define the genotype (21) .
Analyses of Fibrillin Polypeptides. Confluent flasks of fibroblasts from patients and from normal individuals were incubated with [35S]cysteine (NEN) at 50 pkCi/ml in serumfree minimum essential medium without cysteine. After 24 hr, medium was removed and treated with 25 mM diisopropyl fluorophosphate and 3 mM EDTA. The medium was then incubated with gelatin-Sepharose (Pharmacia) on a rotating table for 1 hr. The mixture was poured into a column and the medium that flowed through the gelatin-Sepharose was collected and incubated with fibrillin-specific monoclonal antibody 69 coupled to CNBr-activated Sepharose (Pharmacia) (25) . After incubation for 2 hr on a rotating table, the antibody 69-Sepharose and medium were poured into a column and washed extensively with 0.15 M NaCl/50 mM sodium phosphate, pH 7.5/0.05% Tween 20 , and bound proteins were eluted with 0.1 M glycine/HCl (pH 2.5), neutralized, applied as a sample to an SDS/4.5% polyacrylamide gel, and electrophoresed. The gel was treated with Amplify (Amersham) and the labeled polypeptides were visualized on Kodak X-AR5 film. Preflashed films were developed after exposure overnight or for 3 days.
RESULTS
SSCP Analyses of MFS Patients. The SSCP method was used to screen amplified cDNA fragments of 20 MFS patients for mutations in the coding region of the fibrillin gene. After detection of an aberrantly moving band in SSCP analysis, the specific nucleotide change was identified by direct sequencing of the corresponding PCR product. To date, 6.9 kilobases (kb) of the -10-kb fibrillin cDNA has been cloned, including 5920 bp of coding region followed with 916 bp of the 3' untranslated region (8) . The area of the fibrillin cDNA analyzed covered the known 5920 bp of coding region and first 114 bp of the 3' noncoding region.
Total mRNA was extracted from cultured fibroblasts of MFS patients. After reverse transcription with fibrillinspecific primers, the fibrillin cDNA was amplified in overlapping fragments between 451 bp and 895 bp in size by using nine sets of primers (Fig. 1) . For more sensitive detection of nucleotide changes in the amplified DNA, fragments over 500 bp were cleaved with a suitable restriction enzyme to two fragments of different size. To maximize the sensitivity of the SSCP analyses, each sample was analyzed by nondenaturing electrophoresis under two different conditions.
We found a mobility shift in the DNA fragment of 2 out of 20 analyzed patients, the first in a PCR fragment amplified with primers 7a/b in the sample of patient R.H., a member of a three-generation MFS family, and the second in the fragment amplified with primers 8a/b in a sample of a sporadic Finnish patient, E.Y. (Fig. 1) . Both changes were heterozygous; i.e., the fragment of the normal allele was observed in addition to the shifted fragment.
Identifation of a 366-bp Deletion of the Fibrillin cDNA. A deletion mutation in the sample of patient R.H. was apparent already prior to SSCP analyses, when amplification of the fibrillin cDNA of R.H. with primers 7a/b revealed, in addition to the normal 791-bp fragment, an =425-bp fragment ( Fig. 2A) . A shifted fragment was also observed in SSCP analyses. Sequence analysis ofthe =425-bp fragment showed a deletion of cDNA residues 4762-5127 (Fig. 2B) . Amplification of the fibrillin cDNA of R.H. and his mother (who is also affected) with an alternative primer pair, 12a/b, located internal to primers 7a/b confirmed the 366-bp deletion and proved the cosegregation of the mutation with the disease in this family (Fig. 2C) Proc. Natd. Acad. Sci. USA 89 (1992) Identification of a Nonsense Mutation. The other detected aberrantly moving SSCP fragment was from a Finnish patient, E.Y. (Fig. 1). Here, a heterozygous G-to-A transition at nucleotide 5574 was detected by sequence analysis of the amplified fragment. As a consequence ofthis mutation, a stop codon is substituted for tryptophan, predicting premature termination by 116 amino acids. The G-to-A transition was confirmed in genomic DNA by direct sequencing of the PCR product amplified with the primers 8a/b (Fig. 3A) and also by the solid-phase minisequencing technique (Fig. 3B) . None of the siblings had the mutation, when their DNA samples were analyzed by solid-phase minisequencing.
Protein Analyses of Fibrillin Polypeptides. Both the detected mutations predict shortened polypeptides of fibrillin. Immunoprecipitation analyses with fibrillin-specific antibodies of the medium from metabolically labeled fibroblasts of R.H. and subsequent SDS/PAGE analysis demonstrated that the patient's fibroblasts secreted two species of fibrillin molecules, one normal and the other about 15 kDa smaller (Fig. 4) . This agrees with the calculated molecular mass ofthe deleted amino acids, 15.6 kDa. Northern blot analyses of the patient's total RNA with CLM-5 as a probe did not convincingly show a mRNA deletion, possibly due to the low sensitivity and poor size resolution of this method.
In contrast to the analyses of fibrillin polypeptide chains of R.H., immunoprecipitation analyses with fibrillin-specific antibodies failed to detect a shortened fibrillin polypeptide chain in the medium of the fibroblasts of E.Y., the patient with the point mutation producing an early stop.
Screening of Other Patients for Point Mutations. We used solid-phase minisequencing method to screen DNA samples from 61 MFS patients and 40 controls both for the detected point mutation and for the R239P mutation (Fig. 3B) . Neither mutation was detected in any of the analyzed samples. Genomic DNA was amplified by using 5'-biotinylated primer 10b and the primer lOa. The mutation was detected by a one-step primer extension reaction directed by primer seq 1, which anneals to the DNA directly upstream of the mutation. glycoprotein that is a constituent of the 10-to 12-nm-diameter microfibrils of extracellular matrix (6) .
We have used the published sequence information of fibrillin cDNA to screen for other MFS mutations with the SSCP technique and detected a mutation in 2 of the 20 analyzed patients. The first mutation, which actually did not require SSCP analyses for detection, was a deletion of 122 amino acids shown to segregate in a large three-generation MFS family. The second mutation, found in a sporadic MFS patient, was a nonsense point mutation producing an early stop. As a result, one of the patient's alleles is predicted to code for a truncated fibrillin polypeptide lacking the last 116 amino acids.
In contrast to a previous study (26) in which 9 out of 10 mutations were found by SSCP analysis, the SSCP technique was relatively inefficient here. Possibly this is partially because only two-thirds of the fibrillin cDNA has been cloned, and consequently all the mutations in the 5' third are undetectable. Further, when cDNA copies of mRNA are analyzed, the mutations causing silent alleles or unstable mRNA cannot be detected.
What are the biological consequences of the mutations identified in this study? Like most other MFS patient cell lines (7), immunofluorescence of fibroblasts from both patients displayed reduced amounts of fibrillin fibers (data not shown). Possible explanations include (i) a reduced synthesis and impaired fibrillogenesis due to one mutated fibrillin allele, whose product is either poorly expressed or abnormally retained and degraded intracellularly, or (ii) an amplified deleterious effect on fibrillogenesis due to the secretion and copolymerization of the mutant gene product with normal fibrillin. The latter mechanism occurs in certain type I collagen mutations that result in osteogenis imperfecta: the presence of the mutant product drastically interferes with normal triple-helical assembly, producing the so-called protein suicide (27) . The secretion and copolymerization of the mutant fibrillin gene product with normal fibrillin might equally either slow fibril formation or produce functionally defective structures that are either susceptible to degradation or hamper its interactions with other proteins. These possibilities have been elucidated in vitro in a recent study (28) in which different consequences of unknown MFS mutations were dissected at the protein level.
To date, there are no published data on the consequences of the specified fibrillin mutations in MFS at the protein level.
Here we have shown that fibroblasts from the patient with the 366-bp deletion in the fibrillin mRNA secrete two species of fibrillin. Such shortened polypeptide chains might disturb the multimer formation of fibrillin in the matrix significantly. The deleted area contains 3 of the 34 six-cysteine repeat motifs identified in the coding region of the fibrillin gene (8) . These repeats are thought to participate in the formation of an antiparallel 8-sheet conformation of fibrillin polypeptides.
Immunoprecipitation analyses of polypeptides in the medium of fibroblasts from the patient with the G-to-A transition resulting in an early stop did not show shortened fibrillin molecules. Possible explanations include degradation of the mutant polypeptide chain before or after secretion. It is, however, possible that some of the truncated fibrillin molecules are secreted. Although the details of the assembly process and the stabilization of the fibrillin fibers are not known (29) , a polypeptide lacking a significant portion of its carboxyl-terminal end could result in defective formation of the fibrillin polymers (25) .
Neither of the mutations identified here was observed in the DNA samples of 60 unrelated MFS patients, suggesting that a spectrum of different mutations will be found in the future analyses of MFS families. Definition and detailed characterization of different mutations leading to the MFS phenotype, their characterization at the protein level, and subsequent phenotype-genotype correlations will provide insight into the biological significance of the fibrillin molecule and the specific functions of its various regions.
